Compare REFR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REFR | CTSO |
|---|---|---|
| Founded | 1965 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 45.7M |
| IPO Year | 1995 | 2008 |
| Metric | REFR | CTSO |
|---|---|---|
| Price | $1.00 | $0.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 36.0K | ★ 62.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | N/A |
| Revenue | $1,488,642.00 | ★ $22,503,908.00 |
| Revenue This Year | N/A | $7.29 |
| Revenue Next Year | N/A | $8.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $0.93 | $0.60 |
| 52 Week High | $2.70 | $1.39 |
| Indicator | REFR | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 36.50 | 71.21 |
| Support Level | $0.98 | $0.62 |
| Resistance Level | $1.28 | $0.85 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 12.39 | 84.73 |
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.